Intuitive Surgical (ISRG) on Watch Following Negative Piece on Robots vs. Laparoscopic Surgery in Removing Ovaries, Ovarian Cysts

Intuitive Surgical (Nasdaq: ISRG) is on watch Wednesday following a negative piece in the WSJ late Tuesday.

Highlighted in the upcoming issue of Obstetrics & Gynecology, Jason D. Wright, chief of gynecologic oncology at Columbia, questioned the usage of robotics in removing removing ovaries and ovarian cysts.

While supporters of robotic surgery note that robots use smaller incisions, allow less blood loss, provide for lower pain and postoperative pain medication, the researchers say that regular laparoscopic surgery has similar benefits without having to invest in the new technology, training, and maintenance.

Intuitive makes the da Vinci Surgical System. The company said, following review of the study, the some surgeons choose to use the da Vinci because it can lead to fewer complications and shorter hospital stays. The company also said the technology is often used on patients “with more complex disease and higher risk factors, which the latest study didn't take into account.

Again, the full article is here. Intuitive is up 0.6 percent Wednesday.

You May Also Be Interested In

• Intuitive Surgical (ISRG) PT Lowered to $436 at Baird
• Barinthus Biotherapeutics (BRNS) Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
• Medical device maker Intuitive beats estimates on strong demand for surgical robots